Sagimet Biosciences, Inc. Class A (SGMT) AI Stock Analysis

• Market Cap: $197.48M
• Dividend Yield: N/A
• Average Volume (3M): 578.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.76
• Revenue Growth: N/A
• EPS Growth: -38.23%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 31,001,108
• 10 Day Avg. Volume: 597,424
• 30 Day Avg. Volume: 578,641
• PEG Ratio: 0.59
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.32
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.74
• 1Y Price Target: $28.57
• Price Target Upside: 356.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.94
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $6.00 ▼(-4.15% Downside)

The score is held down primarily by weak financial performance (no current revenue, widening losses, and significant cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these, the balance sheet shows very low leverage and recent corporate developments are constructive (positive MASH combination data and licensing progress), but valuation support is limited given negative earnings and no dividend yield provided.

Positive Factors

Pipeline Progress

Positive Phase 1 trial results for denifanstat and resmetirom combination enhance Sagimet's pipeline, supporting future Phase 2 trials and strategic positioning in metabolic diseases.

Strategic Licensing

The global license agreement with TAPI for resmetirom API strengthens Sagimet's development of a fixed-dose combination product, enhancing its competitive edge in liver disease treatment.

Low Leverage

Sagimet's low leverage reduces financial risk, providing stability and flexibility to pursue long-term strategic initiatives despite ongoing cash burn.

Negative Factors

Cash Burn

Significant cash burn and negative cash flow highlight financial strain, posing a risk to long-term sustainability if not addressed through revenue generation or additional funding.

Widening Losses

Increasing net losses reflect rising operational costs without offsetting revenue, challenging Sagimet's financial health and necessitating efficient cost management.

Zero Revenue

Lack of revenue generation underscores the pre-commercial stage of Sagimet, highlighting the need for successful product commercialization to achieve financial viability.

Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model

Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

How the Company Makes Money

Sagimet Biosciences generates revenue through the development and potential commercialization of its proprietary drug candidates. The company's revenue model is primarily based on progressing its drug pipeline through phases of clinical trials, with the aim of achieving successful regulatory approvals. Additionally, Sagimet may engage in strategic partnerships and licensing agreements with larger pharmaceutical companies, which can provide milestone payments, upfront fees, and royalties on sales. These collaborations can significantly contribute to the company's earnings by providing financial support for research and development activities, as well as expanding market reach. However, as a clinical-stage company, it may currently rely on external funding sources such as venture capital, public offerings, and grants to support its operations.

Sagimet Biosciences, Inc. Class A Financial Statement Overview

Summary

Sagimet Biosciences faces significant financial challenges with persistent losses, negative equity, and high leverage. The reliance on external financing over sustainable free cash flow raises concerns about its long-term viability.

Income Statement

Sagimet Biosciences has shown an erratic revenue pattern with occasional small revenues and significant losses. Despite a brief revenue appearance in 2023, there is a consistent negative EBIT and net income trend, indicating ongoing operational challenges and a lack of profitability. The company is struggling to generate sustainable income, which is critical for future growth and stability.

Balance Sheet

The balance sheet reflects a somewhat stable cash position with a substantial increase in cash and short-term investments in 2024. However, the company has a negative stockholders' equity, indicating high liabilities relative to assets. The debt-to-equity structure is highly unfavorable, suggesting potential financial instability and high leverage risk.

Cash Flow

The cash flow statement reveals negative operating cash flow, indicating the company is not generating sufficient cash from operations. Although there was positive financing cash flow in 2024, it primarily stemmed from external financing rather than operational success. The reliance on external financing over sustainable free cash flow growth poses a risk to long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	2.00M	0.00	0.00	0.00
Gross Profit	0.00	0.00	2.00M	0.00	0.00	0.00
EBITDA	-60.90M	-45.57M	-30.74M	-31.05M	-23.72M	-11.40M
Net Income	-57.67M	-45.57M	-27.88M	-30.50M	-24.44M	-11.37M
Balance Sheet
Total Assets	128.40M	160.26M	96.72M	33.03M	59.03M	68.96M
Cash, Cash Equivalents and Short-Term Investments	116.69M	151.25M	94.90M	32.34M	56.73M	68.70M
Total Debt	115.00K	78.00K	65.00K	211.00K	348.00K	210.00K
Total Liabilities	9.15M	4.45M	5.65M	219.98M	217.29M	204.87M
Stockholders Equity	119.25M	155.81M	91.06M	-186.95M	-158.26M	-135.91M
Cash Flow
Free Cash Flow	-44.84M	-42.44M	-23.77M	-24.49M	-21.71M	-10.42M
Operating Cash Flow	-44.84M	-42.44M	-23.77M	-24.49M	-21.71M	-10.42M
Investing Cash Flow	48.00K	-61.68M	12.58M	-32.01M	0.00	20.00K
Financing Cash Flow	275.00K	104.82M	86.17M	-73.00K	9.74M	68.89M

Sagimet Biosciences, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Positive. The current price of 6.26 is above the 20-day moving average (MA) of 5.99, below the 50-day MA of 6.65, and below the 200-day MA of 6.50, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 70.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGMT.

Sagimet Biosciences, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$158.96M	7.36	19.23%	―	―	―
AVIR	58 Neutral	$276.57M	-1.94	-37.98%	―	―	14.33%
TRDA	52 Neutral	$404.36M	-4.32	-27.11%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMT	48 Neutral	$197.48M	-3.50	-39.78%	―	―	-38.23%
CABA	46 Neutral	$206.97M	-0.82	-101.06%	―	―	-17.21%
CDXS	42 Neutral	$160.78M	-2.37	-114.26%	―	-17.87%	14.42%

Sagimet Biosciences, Inc. Class A Corporate Events

Sagimet Highlights Positive MASH Combo Data and Pipeline Progress

On 18 December 2025, Sagimet Biosciences updated its investor presentation and issued a press release reporting positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its FASN inhibitor denifanstat with the thyroid hormone receptor beta agonist resmetirom, a pairing supported by preclinical evidence of synergistic effects in MASH. The refreshed materials highlight denifanstat’s progress in MASH, where a Phase 2b trial previously met histology primary and multiple secondary endpoints and the program has FDA Breakthrough Therapy designation with Phase 3 readiness, as well as the completion of a Phase 1 hepatic impairment study and the new Phase 1 combination PK data that pave the way for a planned Phase 2 trial in MASH cirrhosis (F4) in the second half of 2026. The company also underscores growing momentum in dermatology, with licensee Ascletis having reported that a Phase 3 acne trial of denifanstat in China met all primary and secondary endpoints and that a new drug application for moderate to severe acne was accepted by China’s NMPA in December 2025, while Sagimet advances TVB-3567 in a first-in-human Phase 1 acne study, collectively strengthening its clinical pipeline and reinforcing its strategic positioning in metabolic and inflammatory diseases.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Biosciences enters global license agreement with TAPI

Sagimet Biosciences Inc. announced its entrance into a license agreement with TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries Ltd., on December 17, 2025. This collaboration grants Sagimet a global, exclusive license to TAPI’s innovative resmetirom active pharmaceutical ingredient (API), supporting the development of a fixed-dose combination (FDC) product featuring denifanstat and resmetirom. The program aims to address critical unmet needs for cirrhosis patients affected by F4-stage MASH. This move marks a significant step forward for Sagimet’s research and development efforts as it aligns with preclinical data showing synergy in treating liver diseases, positioning Sagimet for further advancement in the field.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Biosciences Reports Q3 Results and Updates

On November 13, 2025, Sagimet Biosciences reported its third-quarter financial results and provided corporate updates, including ongoing clinical trials. The company is conducting a Phase 1 trial to assess the pharmacokinetics of a combination of denifanstat and resmetirom, with results expected in the first half of 2026. Additionally, Sagimet’s partner, Ascletis, plans to submit a New Drug Application in China for denifanstat to treat acne. The company also announced leadership promotions and highlighted recent presentations at medical conferences, showcasing positive outcomes in clinical trials for both MASH and acne.

The most recent analyst rating on (SGMT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Biosciences Highlights Drug Development Success

On October 23, 2025, Sagimet Biosciences updated its investor presentation to highlight recent advancements in its drug development pipeline. The company reported successful outcomes in clinical trials for its lead molecule, denifanstat, which met primary endpoints in Phase 2b trials for MASH and Phase 3 trials for acne in China. These developments underscore Sagimet’s strategic positioning in addressing significant unmet medical needs in metabolic diseases and dermatology, potentially enhancing its market competitiveness and stakeholder value.

The most recent analyst rating on (SGMT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.